Gene therapy Archives

In Depth 4 Nov 2020

The Return of Gene Therapy

Gene therapy is a hot area in the biotech industry right now, with many treatments in development and a number of recent approvals. However, the path has not always been a smooth one. Gene therapy has been one of the biggest success stories of the 21st century. Genetic diseases were once seen as incurable, etched […]

November 4, 2020 - 8 minutesmins - By Farhan Mitha

News and Trends 30 Oct 2020

Bayer’s AskBio Acquisition Strong Statement For Gene Therapy in Europe

This week, German big pharma Bayer announced a €3.5B takeover of Asklepios BioPharmaceutical, a well known US gene therapy specialist. This is only one of many examples of the funding windfall experienced by the gene therapy field in 2020. Despite the difficulties posed by the Covid-19 pandemic, 2020 has been a good year for gene […]

October 30, 2020 - 6 minutesmins - By Helen Albert

In Depth 21 Sep 2020

Why Are There Only 11 Cell and Gene Therapies in Europe?

There is a lot of talk about how cell and gene therapy are going to change medicine, so why have only a few of them reached the market? Over the last decade, only 15 advanced therapy medicinal products (ATMPs) – that is, cell and gene therapies – have received approval in Europe. With four withdrawals, […]

September 21, 2020 - 5 minutesmins - By Timothé Cynober

Expert Advice 24 Aug 2020

Why a US Presence Can Help European Biotechs Get Ahead

While there is no doubt that Europe has a thriving biotech scene, it can really help a European company to succeed if it has a US presence. No one knows this better than Patricia Zilliox, CEO of French biotech company Eyevensys, who has lived and worked in the US for many years. Zilliox is French, […]

August 24, 2020 - 5 minutesmins - By Helen Albert

News and Trends 14 Aug 2020

Record Funding for Gene and Cell Therapy Accompanies Turbulent Times

European companies developing advanced therapies such as gene and cell therapies secured at least €2.2B ($2.6B) in the first half of 2020. While this is encouraging in the face of Covid-19, it hasn’t been smooth sailing for all startups in the field, with many struggling to stay afloat during crippling national lockdowns. The funding received […]

August 14, 2020 - 5 minutesmins - By Victor Kotsev

News and Trends 6 Aug 2020

€112M Fund Launched to Commercialize UCL’s Gene Therapy Research

The leading UK institution University College London and the firm AlbionVC have made the first closing of a €112M (£100M) fund with the aim of investing in UCL research and spinouts with a focus on gene and cell therapy. This is the second so-called UCL Technology Fund and could double the size of the first, […]

August 6, 2020 - 2 minutesmins - By Antara Mazumdar

News and Trends 29 Jul 2020

Covid-19 Forces Gene Therapy Companies to Shift Strategy

Amid the Covid-19 pandemic, gene therapy companies are suffering, with clinical trials delayed and investors remaining cautious in an increasingly volatile market. Yet many have set their sights on what could potentially turn into a gold mine: applying their technology to contain the spread of the novel coronavirus. The UK’s Cell and Gene Therapy Catapult […]

July 29, 2020 - 4 minutesmins - By Victor Kotsev

novartis spinal muscular atrophy gene therapy

News and Trends 19 May 2020

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […]

May 19, 2020 - 5 minutesmins - By Jonathan Smith

gene therapy cardiac rare disease biomarin dinaqor

News and Trends 7 May 2020

BioMarin Partners Swiss Biotech to Develop Cardiac Gene Therapies

US biotech BioMarin has partnered Swiss startup DiNAQOR to develop gene therapies to treat rare, inherited cardiac diseases. DiNAQOR will initially receive an upfront payment from BioMarin, followed by developmental, regulatory, and commercial milestone payments and a percentage of royalties on later sales. No financial details of the collaboration were revealed by either company. “We […]

May 7, 2020 - 2 minutesmins - By Helen Albert

Altheia Science gene therapy autoimmune disease

News and Trends 8 Apr 2020

Evotec Makes Move into Gene Therapy with Takeda Deal

German biotech giant Evotec has moved into gene therapy and partnered with Takeda to develop new therapies in oncology, rare diseases, neuroscience, and gastroenterology. The two companies did not reveal financial details of the collaboration, but did say that it will be a multi-year alliance that adds to Evotec’s existing deal with the big pharma […]

April 8, 2020 - 3 minutesmins - By Helen Albert

novartis avexis zolgensma fda data manipulation

News and Trends 2 Apr 2020

Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal

Update (02/04/2020): The FDA has concluded an investigation into a data manipulation scandal surrounding the approval of Novartis’ gene therapy Zolgensma, and has decided against sanctions. The FDA launched an investigation into the manipulated data surrounding the gene therapy application last year, and recently reported that the investigated data violations didn’t meet the threshold for […]

April 2, 2020 - 3 minutesmins - By Jonathan Smith

london ori biotech cell therapy manufacturing

Startup Scout 28 Feb 2020

This Startup Is Automating the Manufacture of Gene and Cell Therapies

In London, the firm Ori Biotech is developing an automated way to manufacture gene and cell therapies, a bottleneck for many biotech companies. Mission: To develop a robotic system to automate the labor-intensive tasks involved in manufacturing cell and gene therapies, such as gene transduction and cell expansion. Gene and cell therapies are maturing as […]

February 28, 2020 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us